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Abstract: The Middle East respiratory syndrome-coronavirus (MERS-CoV), first identified in Saudi
Arabia, is an emerging zoonotic pathogen that causes severe acute respiratory illness in humans
with a high fatality rate. Since its emergence, MERS-CoV continues to spread to countries outside of
the Arabian Peninsula and gives rise to sporadic human infections following the entry of infected
individuals to other countries, which can precipitate outbreaks similar to the one that occurred in
South Korea in 2015. Current therapeutics against MERS-CoV infection have primarily been adapted
from previous drugs used for the treatment of severe acute respiratory syndrome. In search of
new potential drug candidates, we screened a library composed of 2334 clinically approved drugs
and pharmacologically active compounds. The drug saracatinib, a potent inhibitor of Src-family of
tyrosine kinases (SFK), was identified as an inhibitor of MERS-CoV replication in vitro. Our results
suggest that saracatinib potently inhibits MERS-CoV at the early stages of the viral life cycle in
Huh-7 cells, possibly through the suppression of SFK signaling pathways. Furthermore, saracatinib
exhibited a synergistic effect with gemcitabine, an anticancer drug with antiviral activity against
several RNA viruses. These data indicate that saracatinib alone or in combination with gemcitabine
can provide a new therapeutic option for the treatment of MERS-CoV infection.
Keywords: Middle East Respiratory Syndrome; MERS-CoV; Src-family kinase inhibitor;
saracatinib; gemcitabine
1. Introduction
The emergence and re-emergence of infectious diseases represent a significant threat to global
public health and socioeconomic stability as witnessed by numerous outbreaks over the past few
decades [1]. The Middle East respiratory syndrome-coronavirus (MERS-CoV), first identified in
Saudi Arabia in 2012, was the second zoonotic introduction of a highly pathogenic coronavirus into
the human population within a decade [2]. Since its emergence, MERS-CoV continues to spread to
countries outside of the Arabian Peninsula and has caused epidemics with high fatality rates [1,3].
The MERS-CoV is a member of the genus Betacoronavirus in the family Coronaviridae [4,5].
Primary transmission of MERS-CoV is suspected to occur through close contact between humans and
infected animal reservoirs such as dromedary camels [6,7]. Most infections have occurred in Middle
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Eastern countries that are associated with human-to-human spread, typically starting in healthcare
settings that result in sporadic outbreaks [8]. The clinical features of MERS-CoV infection in humans
range from asymptomatic to severe lower respiratory tract infections with the potential development
of acute respiratory distress syndrome, septic shock, and multiorgan failure resulting in death [9,10].
Due to high morbidity and mortality rates, therapeutic options of MERS-CoV were immediately
adapted from previous reports of severe acute respiratory syndrome (SARS) therapies including
the use of broad-spectrum antibiotics, corticosteroids, interferons, ribavirin, lopinavir-ritonavir,
and/or mycophenolate mofetil, but none of them were effective in randomized controlled trials [3,11].
Therefore, the rapid discovery of effective prophylactic or therapeutic measures to prevent or treat
MERS is urgently needed.
Repurposing clinically validated products is a valuable approach for drug discovery, which has
the potential to greatly reduce the time and costs associated with the development and licensure of de
novo therapeutics [12]. Prompt response and availability of a therapeutic option are especially critical
for controlling the spread of highly infectious pathogens such as MERS-CoV. Along these lines, several
Food and Drug Administration (FDA)-approved compounds have been reported to inhibit MERS-CoV
replication in cell culture since its emergence [13–17].
In search of additional MERS-CoV inhibitors, we conducted a screening of 2334 approved drugs
and biologically active molecules using a cytopathic-effect (CPE)-based, high-throughput screening
(HTS) assay. From the results, we identified saracatinib, a potent inhibitor of the Src-family of tyrosine
kinases (SFKs), as an inhibitor of MERS-CoV as well as other members of the Coronaviridae family.
We evaluated the antiviral activity of saracatinib and found that it suppressed the early stages of the
MERS-CoV life cycle in Huh-7 cells through a possible suppression of the SFK signaling pathways.
Furthermore, we assessed the combined effect of saracatinib with another chemotherapeutic agent,
gemcitabine, in Huh-7 cells. Enhanced effects with lower toxicity were observed in a combination of
these two drugs. Data presented in this study suggest that saracatinib alone or in combination with
other agents can provide a new therapeutic option for the treatment of MERS-CoV infection.
2. Materials and Methods
2.1. Cells and Viruses
African green monkey Vero (ATCC® CCL-81) and human lung fibroblast MRC-5 (ATCC®
CCL-171) cells were purchased from American Tissue Culture Collection (ATCC®, Manassas, VA,
USA). Human hepatoma Huh-7 and Crandell Reese feline kidney (CRFK) cells were obtained from
Japan Cell Research Bank (National Institutes of Biomedical Innovation, Health and Nutrition, Japan)
and Korean Cell Line Bank (KCBL, Seoul, Republic of Korea), respectively. Vero and Huh-7 cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM, HyCloneTM, Logan, UT, USA)
supplemented with 10% fetal bovine serum (FBS, HyCloneTM) at 37 ◦C in a 5% CO2 incubator. MRC-5
and CRFK cells were grown in minimal essential medium (MEM, HyCloneTM) supplemented with
10% FBS at 37 ◦C in a 5% CO2 incubator.
Patient-derived isolate MERS-CoV (passage 4, MERS-CoV/KOR/KNIH/002_05_2015; GenBank
accession No. KT029139.1) [18] was kindly provided by the Korea Centers for Disease Control and
Prevention (KCDC, Osong, Republic of Korea). The working virus stock (passage 4) was propagated
in Huh-7 cells. Briefly, the MERS-CoV/KOR/KNIH/002_05_2015 strain was inoculated into Huh-7
cells and incubated at 37 ◦C until >90% CPE was visible. The recombinant MERS-CoV (rMERS-CoV)
and rMERS-CoV with mutation in spike 2 (S2) protein (designated rMERS-CoV S2) were passaged
once on Vero cells upon receipt for stock preparation. The virus-containing supernatants were
collected, clarified by centrifugation, and aliquots were stored at −80 ◦C until further use. Virus
stocks were titrated by plaque assay using Vero cells as previously described [19]. All procedures
using live MERS-CoV were performed in a biosafety level-3 facility at Virus Research Group, Korea
Research Institute of Chemical Technology (KRICT), Daejeon, Republic of Korea. Human coronavirus
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229E (HCoV-229E, ATCC® VR-740) and betacoronavirus OC43 strain (OC43, ATCC® VR-1558) were
purchased from ATCC® and amplified in MRC-5 cells. Feline infectious peritonitis virus (FIPV, ATCC®
VR-990) was purchased from ATCC and amplified in CRFK cells.
2.2. Chemical Compounds and Antibodies
Saracatinib (AZD0530; 99.9% purity) was purchased from Selleckchem (Houston, TX, USA)
and gemcitabine hydrochloride (≥98% purity) was obtained from Sigma-Aldrich (St. Louis, MO,
USA) for further analysis. All compounds were prepared in 100% dimethyl sulfoxide (DMSO,
Sigma-Aldrich). Rabbit anti-MERS-CoV nucleocapsid (N) antibody was purchased from Sino Biological
Inc. (Cat. 100211-RP02, Beijing, China). Antibodies against Fyn (4023), Lyn (2796), Src (2123), and
Yes (3201) were purchased from Cell Signaling Technology (Danvers, MA, USA). The loading control,
the anti-β-actin monoclonal antibody, was purchased from Sigma-Aldrich. Horseradish peroxidase
(HRP)-conjugated goat anti-rabbit and anti-mouse secondary antibodies were purchased from Thermo
Fisher Scientific (Waltham, MA, USA).
2.3. Small-Molecule Compound Libraries
The following compound libraries were used in this study: (i) the Pharmakon-1600 collection
(Microsource Discovery Systems, Gaylordsville, CT, USA) comprised of FDA-approved drugs and
drug substances approved for use in Europe or Asia; (ii) the Prestwick Chemical Library (Prestwick
Chemical, San Diego, CA, USA) consisting of 326 mostly approved drugs (FDA, European Medicines
Agency and other agencies); (iii) the Tocriscreen library (Tocris Bioscience, Bristol, United Kingdom)
consisting of 103 FDA-approved compounds; and (iv) an in-house library comprised of 305 biologically
active compounds including known drugs, experimental bioactive compounds, and pure natural
products deposited in the Korea Chemical Bank at KRICT (Daejeon, Republic of Korea). All library
compounds were dissolved in DMSO.
2.4. Primary Screening Assay
A CPE-inhibition assay was used to screen for inhibitors of MERS-CoV as previously
described [19]. Briefly, Huh-7 cells were seeded in 96-well plates at a density of 2 × 104 cells/well.
After overnight incubation of the cells at 37 ◦C, equal volumes of MERS-CoV inoculum (multiplicity of
infection [MOI] 0.1) and compound dilution (final concentration of 20 µM) were added and incubated
at 37 ◦C in a 5% CO2 incubator for three days. On day three, post-infection (p.i.), cell viability was
measured using the CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS, Promega,
Madison, WI, USA), according to the manufacturer’s instructions. Absorbance at 490 nm (A490) was
measured using a SynergyTM H1 multi-mode microplate reader (Biotek, Winooski, VT, USA). Percent
inhibition was calculated using the values of maximum infectivity derived from infected cultures
treated with 0.5% DMSO (virus control, 0% inhibition) and background derived from mock-infected
treated with 0.5% DMSO (cell control, 100% inhibition) as references using the formula ([sample −
virus control]/[cell control − virus control] × 100). The statistical validity of the MERS-CoV primary
screening system was determined by calculating for the Z’-factor using the values derived from virus
control and cell control wells [20]. For the primary screening, a Z’-factor ≥0.5 and a coefficient of
variation (CV) among the controls ≤10% was used to validate the results of the assay. The antiviral
activity of hit compounds was determined from the dose-response curve (DRC), and the 50% effective
concentration (EC50) and the compound-specific toxicity (50% cytotoxic concentration [CC50]) were
calculated with GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA) using the non-linear
regression formula: log (inhibitor) vs. response-variable response (four parameters) model.
2.5. Time-Of-Addition Assay
One day prior to infection, Huh-7 cells (5 × 104 cells/well) were seeded in a 12-well tissue
culture plate. The next day, cells were infected with MERS-CoV at an MOI 0.02 for 1 h at 37 ◦C.
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After 1 h, the unbound virus was removed by washing with phosphate-buffered saline (PBS, pH 7.4).
Compounds were added to cells at specific time points during virus infection as follows: pre, 1 h prior to
virus infection; co-treatment during virus infection; post, 1 h and 4 h after virus infection. The antiviral
activity of the compound was analyzed after 24 h p.i. by measuring the number of infectious viral
particles and intracellular viral RNA expression levels using plaque assay and RT-qPCR, respectively.
In addition, the time-of-addition experiment combined with temperature-shifting assay was
performed. Briefly, Huh-7 cells were inoculated with MERS-CoV at 4 ◦C for 1 h (attachment/binding).
The unadsorbed virus was removed by washing three times with ice-cold PBS and replenished with
fresh culture medium. Subsequently, plates were shifted to 37 ◦C to allow synchronous entry and
infection. Saracatinib was treated during the 4 ◦C incubation only or added at specific time points
during the 37 ◦C incubation. The antiviral activity of the compound was analyzed after 24 h p.i. by
measuring the number of infectious viral particles and intracellular viral RNA expression levels using
plaque assay and RT-qPCR, respectively.
2.6. Viral Plaque Assay
Infectious MERS-CoV titers were determined by plaque assays as described previously (19).
Briefly, Vero cells were seeded in 6-well plates at 5 × 105 cells/well and cultured overnight at 37 ◦C in
a 5% CO2 incubator. Cells were inoculated with ten-fold serially diluted cell culture supernatants for
1 h at 37 ◦C. After adsorption, cells were washed with PBS and overlaid with DMEM containing 0.5%
agarose (MP Biomedicals, Solon, OH, USA) and 2% FBS. After three days of incubation, plaques were
visualized by staining with 50 µg/mL neutral red (Sigma-Aldrich).
2.7. Quantitative Real-Time Reverse-Transcription PCR (RT-qPCR) Analysis
Total cellular RNA was purified using the RNeasy Mini kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s instructions. The RT-qPCR was performed using a SuperScript III one-step
RT-qPCR system with Platinum Taq polymerase (Thermo Fisher Scientific), primers/probe sets
targeting open reading frame 1a (ORF1a) or upE genes (Table S1) and a QuantStudio 6 real-time PCR
system (Applied Biosystems, Foster City, CA, USA) as described previously [21]. The relative viral RNA
expression levels (fold change) were calculated by the ∆∆CT method and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as the endogenous control. Two biological replicates, each with
technical duplicates, were used for quantification.
2.8. Western Blot Analysis
Huh-7 cells were infected with MERS-CoV at an MOI of 0.02 or mock-infected and treated with
ten-fold serial dilutions of each compound. At 24 h p.i., cells were washed with PBS and lysed
using NP40 cell lysis buffer (Thermo Fisher Scientific) containing 0.5% protease inhibitor cocktail
(Pierce, Rockford, IL, USA). The cell lysates were clarified by centrifugation and total protein content
was determined by the Bradford Protein assay (Bio-Rad, Hercules, CA, USA). Equal amounts of
protein were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
electro-transferred to a polyvinylidene fluoride (PVDF) membrane (Immobilon®-P PVDF membrane,
Merck Millipore, County Cork, Ireland). The membrane was blocked in Tris-buffered saline/T (0.1%
Tween®20, Sigma-Aldrich) containing 5% skim milk for 2 h at room temperature. MERS-CoV N
protein was detected using a primary antibody specific for viral N protein, followed by a horseradish
peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody. The cellular β-actin protein,
a loading control, was detected with an anti-β-actin-specific primary antibody and HRP-conjugated
goat anti-mouse secondary antibody. After the addition of a chemiluminescent HRP substrate
(SuperSignal West Pico Chemiluminescent Substrate; Pierce), images were obtained using a LAS-4000
Luminescent Image Analyzer (Fujifilm, Tokyo, Japan).
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2.9. RNAi
Huh-7 cells were transfected with pools of two or three specific small interfering RNAs (siRNAs)
against human Fyn (GeneID 2534), Lyn (Gene ID 4067), Src (GeneID 6714) or Yes (GeneID 7525) or
a siRNA universal negative control (Bioneer, Daejeon, Republic of Korea) to a final concentration of
100 nM by using Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) according
to the manufacturer’s instructions. Efficient knockdown of the targets was monitored by Western blot
analysis at 48 h after siRNA transfection.
2.10. In Vitro Drug-Drug Combination Assay
To evaluate the drug combination effect in vitro, saracatinib was combined with gemcitabine.
Different concentrations of a serially-diluted single compound were combined as dose matrices and
MERS-CoV inhibition was evaluated by the CPE-inhibition assay as described above. Combination
indices (CI) were calculated by using CompuSyn software (ComboSyn Inc., Paramus, NJ, USA)
according to Loewes’ additivity model as described previously [22].
3. Results
3.1. Identification of Saracatinib as an Anti-MERS-CoV Hit Compound
In order to identify compounds with antiviral activity against MERS-CoV, we employed
a cell-based antiviral screening assay based on the protection of cells from viral CPE. The primary screen
of 2334 clinically approved drugs and pharmacologically active compounds (final concentration of
20 µM) identified 63 compounds with MERS-CoV antiviral activity above the cut-off (>47% inhibition),
yielding a hit rate of 2.6% (Figure 1A). The average Z’ score during the primary screen was 0.80 ± 0.08,
indicating that the assay was robust and reliable for the detection of potential MERS-CoV inhibitors
(Figure S1). Further confirmation of the antiviral activity of selected compounds against MERS-CoV
infection was performed by testing them in complete dose-response analyses ranging from 0.62 µM
to 50 µM and the EC50 and CC50 values were determined. Using this method, we determined 12
hit compounds, primarily classified as antiprotozoal, anticancer and antipsychotics, active against
MERS-CoV with micromolar EC50 values ranging from 2.1 µM to 14.4 µM (Table 1). Among the
identified hits, saracatinib (AZD0530, Figure 1B) was particularly promising as it exhibited prominent
antiviral activity with an estimated EC50 of 2.9 µM and a CC50 of >50 µM, resulting in selectivity
index (SI) of approximately >17 (Figure 1C). Prior to proceeding further, we tested whether saracatinib
displayed antiviral activity against different strains of MERS-CoV. Huh-7 cells were infected with
the recombinant MERS-CoV (rMERS-CoV) derived from the EMC/2012 strain and a cell culture
adapted variant derived from this virus (rMERS-CoV-S2). From the results, saracatinib exhibited
an EC50 of 9.3 µM and 9.0 µM against rMERS-CoV and rMERS-CoV-S2, respectively, suggesting
a broad-spectrum anti-MERS-CoV activity of the drug (Figure 1D). Moreover, saracatinib showed
a broad-antiviral activity against other human coronaviruses such as hCoV-229E and OC43 with an
EC50 2.4 µM and 5.1 µM, respectively, and feline infectious peritonitis virus (FIPV) with an EC50 of
7 µM within a non-toxic range of concentrations (Table S2).
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Table 1. Hit compounds with antiviral activity against MERS-CoV.
No. Compound EC50 (µM) † CC50 (µM) † Pharmaceutical Class Mode of Action
1 Nutlin-3 6.9 ± 1.4 26.8 ± 1.6 Antiviral, anticancer MDM2 inhibitor
2 Hydroxyzine pamoate 14.4 ± 3.4 >50 Antihistamine Cholinergic system modulator
3 Amodiaquine dihydrochloride § 2.1 ± 0.7 12.3 ± 5.9 Antiprotozoal Histamine N-methyltransferase inhibitor
4 Amodiaquine dihydrochloride dehydrate § 2.4 ± 0.7 13.2 ± 5.0 Antiprotozoal Histamine N-methyltransferase inhibitor
5 Chloroquine diphosphate § 12.0 ± 3.0 >50 Antiprotozoal Hemozoin formation inhibitor
6 Hydroxychloroquine sulfate § 13.3 ± 2.1 >50 Antiprotozoal Hemozoin formation inhibitor
7 Saracatinib 2.9 ± 0.6 57 ± 5.5 Anticancer Tyrosine kinase inhibitor
8 Sotrastaurin 9.7 ± 3.3 >50 Anticancer Protein kinase C inhibitor
9 Acetophenazine maleate 11.2 ± 5.0 23.6 ± 3.8 Antipsychotic Dopamine receptor antagonist
10 Dosulepin hydrochloride 3.4 ± 0.0 28.9 ± 0.0 Antidepressant Serotonin/noradrenaline reuptake inhibitor
11 Methotrimeprazine maleate salt 2.5 ± 0.0 24.5 ± 0.0 Antipsychotic Dopamine receptor antagonist
12 N1-(4-pyridyl)-2-chloro-5-nitrobenzamide 10.5 ± 0.3 >50
§ MERS-CoV antiviral activity also described by Dyall et al. [14]. † The 50% effective concentration (EC50) and the 50% cytotoxic concentration (CC50) were calculated using the non-linear
regression formula.
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3.2. Saracatinib Inhibits MERS-CoV Replication In Vitro
To determine whether saracatinib directly inhibits MERS-CoV infection, we first assessed the effect
of saracatinib on the production of MERS-CoV infectious progeny virus. The number of viral titers
was measured in the cell culture supernatant of saracatinib-treated Huh-7 cells following the infection
with MERS-CoV by the plaque assay. As shown in Figure 2A, a dose-dependent reduction in infectious
MERS-CoV titer exceeding 50% was observed at 1 µM and close to 90% at 10 µM saracatinib as
compared to untreated controls. Treatment of 0.1 µM saracatinib resulted in only marginal reduction of
viral titer. Next, we assessed its impact on the expression of viral N protein and synthesis of MERS-CoV
RNA by Western blot analysis and RT-qPCR, respectively. We infected Huh-7 cells with MERS-CoV
at an MOI of 0.02 and harvested total cell lysate at 24 h p.i. Western blot analysis showed a nearly
complete abrogation of viral N protein expression in infected cells treated with 10 µM saracatinib,
whereas treatment of saracatinib at 1 µM or lower did not affect the expression of viral N protein levels
(Figure 2B). Consistent with a reduction in viral titer, a dose-dependent reduction in both intracellular
viral genomic (ORF1a; Figure 2C) and viral mRNAs (upE; Figure 2D) was observed in infected-cells
treated with saracatinib when compared to those of untreated controls. Treatment of 10 µM saracatinib
resulted in near complete inhibition of both intracellular viral genomic and mRNA syntheses. Together,
these data confirm the in vitro anti-MERS-CoV activity of saracatinib by reducing the production of
progeny virus as well as the expression of both viral RNA and protein levels at a micromolar range.
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Figure 2. In vitro antiviral activity of saracatinib against MERS-CoV. Antiviral efficacy of saracatinib
against MERS-CoV in Huh-7 cells. MERS-CoV infected Huh-7 cells were treated with saracatinib at
indicated concentrations for 24 h, after which culture supernatant and cell lysates were collected.
(A) Amount of infectious viral particles released to culture supernatants was determined by
plaque assay. (B) MERS-CoV nucleocapsid (N) protein levels in lysates of infected cells were
determined by Western blot analysis. Immunoblot detection of β-actin is shown as a loading control.
(C,D) Quantification of intracellular MERS-CoV RNAs by RT-qPCR assay. Total RNA was isolated
from lysates of infected cells for quantification of intracellular MERS-CoV RNA levels (ORF1a and
upE) and results were normalized to GAPDH mRNA. Data represent means (±SD) of at least two
independent experiments performed in duplicate. Significant differences are indicated by * p < 0.05,
** p < 0.01, *** p < 0.001, **** p < 0.0001.
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3.3. Saracatinib Inhibits the Early Stages of MERS-CoV Replication
To investigate which step(s) of the MERS-CoV life cycle were affected by saracatinib,
a time-of-addition/removal experiment was performed. Saracatinib (10 µM) was added to Huh-7
cells either 1 h prior to (pretreatment), during (co-treatment), 1 h or 4 h after infection (post-treatment)
with MERS-CoV (Figure 3A). At 24 h p.i., the amount of released virus particles into the cell culture
supernatant was determined by plaque assay. As shown in Figure 3B, saracatinib treatment prior
to infection resulted in a similar viral titer when compared to untreated cells, indicating that the
blockage of cellular receptor(s) was not its mode-of action. To clarify the possibility that saracatinib
interacts directly with virus particles or cellular receptors, virus attachment was performed at 4 ◦C
in the presence or absence of saracatinib. After 1 h adsorption, cells were washed and replenished
with fresh media followed by incubation at 37 ◦C to allow virus internalization. The virus titer
in cell culture supernatant from saracatinib-treated cells during incubation at 4 ◦C was similar to
that of untreated cells, suggesting that saracatinib does not interact either with the virus particles
or cellular receptors [23]. In contrast, the addition of the drug during virus infection at 37 ◦C
resulted in a marked reduction of the viral titer (Figure 3B, co [p = 0.08]) as well as a significant
decrease in the intracellular viral genomic RNA and mRNA expressions (Figure S2). Moreover,
the reduction of MERS-CoV titer became more pronounced when 10 µM saracatinib was added 1 h
after virus inoculation indicating that the drug interfered with the early stages of viral replication
after internalization (Figure 3B, post [1–22,24,25]). The antiviral activity became less effective when
saracatinib was added after 4 h post-inoculation (Figure 3B, post [4–22,24,25]). The inhibitory effect was
prominent on the accumulation of intracellular MERS-CoV RNAs. The syntheses of both intracellular
viral genomic RNA and mRNAs were severely affected upon treatment of the drug when added 1 h
(post [1–22,24,25]) after virus inoculation (Figure S2). To more precisely understand the time window
of the saracatinib-mediated inhibition of MERS-CoV replication, 10 µM saracatinib was added to
infected cells at different time points after infection and remained present until sample collection
(Figure 3C). At 24 h p.i., infectious particles and intracellular MERS-CoV genomic RNA and mRNAs
were quantified as mentioned above. As shown in Figure 3D–F, saracatinib added within the first 2 h
p.i. resulted in a significant reduction (~80%) in infectious virus titers and near complete inhibition
of both viral genomic RNA and mRNA syntheses. Together, these data suggest that saracatinib most
potently inhibits the early stages of MERS-CoV life cycle after internalization.
Viruses 2018, 10, 283 10 of 19
Viruses 2018, 10, x FOR PEER REVIEW  10 of 19 
 
 
Figure 3. Saracatinib inhibits the early stages of MERS-CoV life cycle. (A) Schematic representation of 
time-of-addition/removal experiment. (B) Huh-7 cells were treated with 10 μM saracatinib for 1 h 
prior to virus infection (pre) or 0.5% DMSO (virus control, VC), for 1 h during infection (co), at 1 h 
post-infection (post 1–24), and at 4 h post-infection (post 4–24). After 24 h, the amount of infectious 
viral particles released to culture supernatants was determined by plaque assay. All values represent 
means ± SD of two independent experiments performed in duplicate. Significant differences are 
indicated by * p < 0.05. (C) Schematic representation of time-of-addition experiment. Huh-7 cells 
were inoculated with MERS-CoV at 4 °C to allow attachment/binding. After 1 h incubation, plates 
were shifted to 37 °C to allow synchronous entry and infection. Saracatinib (10 μM) was treated 
during the 4 °C incubation only or added at indicated time points during the 37 °C incubation and 
remained present until sample collection. After 24 h p.i.; (D) cell culture supernatants were collected 
Figure 3. Saracatinib inhibits the early stages of S-CoV life cycle. (A) Schematic representation
of time-of-addition/removal experiment. (B) uh-7 cells were treated with 10 µM saracatinib for 1 h
prior to virus infection (pre) or 0.5% DMSO (virus control, VC), for 1 h during infection (co), at 1 h
post-infection (post 1–24), and at 4 h post-infection (post 4–24). After 24 h, the amount of infectious
viral particles released to culture supernatants was determined by plaque assay. All values represent
means ± SD of two independent experiments performed in duplicate. Significant differences are
indicated by * p < 0.05. (C) Schematic represent ti n of time-of-ad tion experiment. Huh-7 cells were
inoculated with MERS-CoV at 4 ◦C to allow attachment/binding. After 1 h incubation, plates were
shifted to 37 ◦C to allow synchronous entry and infection. Saracatinib (10 µM) was treated during
the 4 ◦C incubation only or added at indicated time points during the 37 ◦C incubation and remained
present until sample collection. After 24 h p.i.; (D) cell culture supernatants were collected for virus
titration using plaque assay. (E,F) Total RNA isolated from infected lysates was used for analyses
of intracellular MERS-CoV genomic RNA (ORF1a) and mRNA (upE) by qRT-qPCR. Data represent
the means ± SD of two independent experiments performed in duplicate. Significant differences are
indicated by * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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3.4. MERS-CoV Replication is Affected by Knockdown of Fyn and Lyn Kinases
As previously mentioned, saracatinib has significant inhibitory activity against several members
of SFKs as well as Abelson (Abl) kinase [24,25]. Next, we investigated the role(s) of members of SFKs
(Fyn, Lyn, Src, and Yes) in the MERS-CoV replication expressed in Huh-7 cells. Using a RNAi-based
approach, expression of these kinases was knocked down in Huh-7 cells prior to MERS-CoV infection.
Significant knockdown of targeted kinases was achieved in Huh-7 cells as confirmed by Western blot
analyses at 48 h post-siRNA transfection (Figure 4A). The siRNA-transfected cells were infected with
MERS-CoV at an MOI of 0.02. At 12 h p.i., we observed significant reductions in virus titer when Huh-7
cells were knocked down of Fyn and Lyn kinases with siRNA (Figure 4B). In contrast, no significant
inhibition of MERS-CoV replication was observed in Yes-knocked down cells. The extent of Src kinase
knock down was not efficient enough to determine the role of the kinase during MERS-CoV replication
in our study. Nevertheless, the data suggest that expression of Fyn and Lyn kinases may be necessary
for efficient MERS-CoV replication.
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Figure 4. MERS-CoV is sensitive to RNA-mediated depletion of Fyn and Lyn kinases. (A) Specific
knockdown of Fyn, Lyn, Src, and Yes kinases. Huh-7 cells were transfected with 100 nM nontargeting
(NT) siRNA or siRNAs targeting Fyn, Lyn, Src, and Yes mRNA. At 48 h post-transfection, the cells
were infected with MERS-CoV at an MOI of 0.02. After 12 h of infection, lysates of infected cells
were collected and subjected to Western blot analyses. The β-actin was used as the loading control.
The result of a representative experiment out of two repeats is shown. (B) Specific knockdowns of Fyn
and Lyn interfere with the production of infectious MERS-CoV from siRNA transfected cells. Data
presented is from means ± SD of 3 independent experiments. Significant differences are indicated by
* p < 0.05, ** p < 0.01.
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3.5. Synergistic Antiviral Effect of Saracatinib in Combination with Gemcitabine
Finally, we explored the possibility of using saracatinib as a combinatorial therapy with other
clinically available drugs. Gemcitabine is a deoxycytidine analog that is commonly used for the
treatment of cancers [26,27] (Figure 5A). Recently, several studies have shown its broad-spectrum
antiviral effect on enteroviruses and highly pathogenic coronaviruses including MERS-CoV and
SARS-CoV [14,28]. Prior to analyzing the efficacy of 2-drug combination, we confirmed the
anti-MERS-CoV potential of gemcitabine in our cell-based assays. Briefly, gemcitabine treatment
showed a convincing dose-dependent antiviral effect in Huh-7 cells with an EC50 of 1.2 µM at
a non-cytotoxic concentration range (Figure 5B). Subsequently, treatment with a 1 µM or higher
dose of gemcitabine completely abolished the production of infectious MERS-CoV particles as well
as the expression of viral N protein expression assessed by plaque assay and Western blot analysis,
respectively (Figure 5C,D).
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Figure 5. In itr antiviral activity of gemcitabine against MERS-CoV. (A) The structure of gemcitabine.
(B) Antiviral pote cy of gemcitabine a ainst MERS-CoV. The antiviral EC50 (black squares) and CC50
(grey circles) of gemcitabine were d termined by dose-response curve (DRC) analyses as described
in Figure 2. (C,D) Antiviral efficacy of gemcitabine ag inst MERS-CoV in Huh-7 cells. MERS-CoV
infected Huh-7 cells were treated with gemcitabine at indicated concentrations for 24 h, after which the
culture supernatant and cell lysates were collected. (C) Amount of infectious viral particles released to
culture supernatants was determined by plaque assay. (D) MERS-CoV N protein levels in lysates of
infected cells were determined by Western blot analysis. The immunoblot detection of β-actin is shown
as a loading control. Data represent means (±SD) of at least two independent experiments performed
in duplicate. Significant differences are indicated by * p < 0.05.
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Next, we investigated the effects of saracatinib in combination with gemcitabine. MERS-CoV
infected Huh-7 cells were simultaneously treated with a dose range of 0, 1/8, 1/4, 1/2, 1, 2, and 4
of EC50 of saracatinib and gemcitabine and the combined antiviral effect was assessed using the
colorimetric cell viability assay (Figure S3). The combination index (CI) was calculated according to
the methods of Chou et al. [14] and analyzed using CompuSyn software. The 2-drug combination
of saracatinib with gemcitabine showed a considerable synergistic antiviral effect with a CI value
of 0.529 (CI < 1, =1, and >1 indicated synergism, additive effect, and antagonism, respectively;
Table 2). Moreover, it is noteworthy that the combined treatment with 2-drugs showed no differential
cytotoxicity when compared to that of saracatinib alone. Importantly, a combination of saracatinib
with gemcitabine showed less cytotoxicity than gemcitabine alone in Huh-7 cells, indicating that it
is suitable for use in low-dose combination therapy than the individual drugs used alone (Figure 6).
Together, these results suggest that saracatinib can be used effectively in combination with gemcitabine
against MERS-CoV infection.
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Figure 6. Cytotoxicity of gemcitabine and saracatinib, alone or in combination, in Huh-7 cells.
Cells were treated with increasing concentrations of gemcitabine or saracatinib alone, or in combination
for 48 h and cell viability was measured using the CellTiter 96® AQueous One Solution Cell Proliferation
Assay. Data represent means (±SD) of at least two independent experiments performed in duplicate.
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Saracatinib +
Gemcitabine 1:1 1.260 0.696 0.434 0.334 0.529 +++ Synergism
a Data analysis was performed using CompuSyn software (ComboSyn, Inc.). Data represent mean of the average of
two independent experiments (n = 2). b Weighted average combination index (CI) values were determined as CIwt
= [CI50 + 2 × CI75 + 3 × CI90 + 4 × CI95]/10. c Degree of synergism (+ signs) is based on the ranges of CI values as
described previously [22].
4. Discussion
In this study, we described the antiviral activity of saracatinib against MERS-CoV infection
in Huh-7 cells. Saracatinib (AZD0530), developed for the treatment of tumor malignancies [25],
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was identified by screening anti-MERS-CoV activity of 2334 approved drugs and biologically active
molecules using a CPE-based HTS assay. From the primary screening, we identified several drugs
including chloroquine, amodiaquine, and chloropromazine analogs that have previously been reported
as inhibitors of the MERS-CoV by other groups [13,14], indicating the validity of our screening
results. In addition, we found two neurotransmitter inhibitors, dosulepin and hydroxyzine pamoate,
with different chemical core structures to those previously reported that inhibited the replication of
MERS-CoV in vitro at micromolar concentrations. Moreover, a protein kinase C inhibitor, sotrastaurin,
undergoing clinical trials for the prevention of organ transplant rejection and psoriasis treatment [29],
also blocked MERS-CoV infection in Huh-7 cells with an EC50 of approximately 9.7 µM with low
cellular toxicity (CC50 > 50 µM). However, the SI of these molecules were limited (<10) when compared
to that of saracatinib, which was selected for further studies.
Saracatinib is an orally available small molecule that are potent SFK members and Abl kinases by
blocking their ATP-binding sites [25]. The SFKs and related kinases play a central role in the regulation
of multiple signal transduction pathways involved in gene transcription, cytoskeleton organization,
and cell proliferation that are essential for viral replication [30–32]. Several research groups have
demonstrated that SFKs are associated with diverse aspects of viral infections including the induction
of the antiviral immune response [33,34] as well as the facilitation of viral entry such as coxsackievirus,
influenza A virus, Ebola virus, and Kaposi’s sarcoma-associated herpesvirus [35–39], RNA replication
of hepatitis C virus [40,41], West Nile virus assembly [42], and regulation of multiple stages of human
immunodeficiency virus-1 replication [43–46].
Our data showed that saracatinib inhibited MERS-CoV replication by reducing virus titers at
a micromolar range. The production of infectious virus particles as well as syntheses of viral genomic
RNA and mRNAs were severely affected when saracatinib was added to cells and left for the first
4 h of virus infection while its antiviral effect was significantly reduced when the drug was added
after 4 h of infection, suggesting that the drug inhibits the early stages of the MERS-CoV life cycle.
Subsequently, we aimed to identify the target(s) of saracatinib involved in MERS-CoV infection by the
RNAi-depletion of Fyn, Lyn, Src, and Yes, expressed in Huh-7 cells. Our data showed that knockdown
of Fyn or Lyn resulted in a significant reduction in MERS-CoV titers, although the effects were less
severe when compared to those of saracatinib treatment. The difference could be explained by the
fact that saracatinib is a pan-SFK selective agent that potently inhibits several members of SFKs as
well as other nonreceptor tyrosine kinases such as Abl [25], suggesting that multiple kinases might be
involved in MERS-CoV infection. In addition, the ubiquitous expression of some members of SFKs
leads to a high level of functional redundancy where the remaining SFK members compensate for those
that are functionally inactive. Regrettably, we could not definitely determine whether the depletion of
Src kinase activity alone or in combination with other members of SFKs had a detrimental effect on
MERS-CoV replication due to the experimental limitations of using siRNA-based knockdown assays.
This is particularly important since previous studies have demonstrated that multiple members of
SFKs, especially the Src, Fyn, and Yes kinases, often in conjunction with Abl kinase, play an important
role in the life cycle of various viruses [39,47–49]. Recently, Coleman et al. indicated that Abl2,
the imatinib target, was required for efficient SARS-CoV and MERS-CoV replication in vitro [17]. In
a follow up study, Sisk et al. [50] demonstrated that Abl kinase activity and associated pathways
were involved in the coronavirus fusion step with endosomal membrane as well as cell-cell fusion
that occurs late in infection. Thus, we speculate that the anti-MERS-CoV activity of saracatinib is
mediated similarly via the inhibition of multiple members of SFKs including Fyn/Lyn together with
Abl2 kinase. The exact mechanism of the action of multiple members of SFKs together with Abl2
kinase and associated pathways involved in MERS-CoV replication is currently under investigation in
our laboratory.
Due to the central function of individual SFKs in many signaling pathways such as the EGF
receptor (EGFR), Ras/Raf/MEK, PI3K/AKT, and JAK/STAT pathways [30,51] involved in cell
metabolism, there are other possible mechanisms by which Fyn/Lyn or other members of SFKs may
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affect the infectious cycle of MERS-CoV and other coronaviruses. Along these lines, a previous study
on the kinome analysis of MERS-CoV infection indicated that ERK/MAPK intermediates, in particular
MEK1/2 and ERK1/2, play important roles during the course of infection [16]. Similarly, in the closely
related murine coronavirus mouse hepatitis virus (MHV), inhibitory effects on phosphorylation of
the substrate ERK1/2 by specific inhibitor of MEK1/2 resulted in the strong suppression of MHV
propagation at the step of viral RNA synthesis in culture cells [52,53]. From these findings, we inferred
that the suppression of SFK resulted in the negative regulation of downstream signaling responses such
as ERK/MAPK and PI3K/AKT/mTOR pathways, which in turn have adverse effects on coronavirus
replication. However, the effects of saracatinib on these various signaling pathways remain to be
further elucidated.
Several FDA-approved tyrosine kinase inhibitors are actively used in the clinic or in clinical trials for
cancer treatment, however, increasing evidence has shown that cells acquire resistance to these agents by
activating a modified signaling pathway to replace the lack of a signal in target therapy [54]. To overcome
these limitations, we evaluated the combined effects of saracatinib with another chemotherapeutic agent,
gemcitabine, with a different mechanism of action to compensate for any drug resistance that may arise.
Gemcitabine, an FDA-approved anticancer drug, is a deoxycytidine analog that interferes with normal
DNA/RNA synthesis through the inhibition of ribonucleoside reductase [55]. Previous studies have
shown that gemcitabine exhibits a broad spectrum antiviral effect against several RNA viruses including
the influenza virus, enteroviruses, and coronaviruses [14,28,56–58]. Co-treatment of saracatinib with
gemcitabine showed a synergistic antiviral effect and minimal cytotoxic effect, supporting the idea of
using them in a combination therapy to potentiate efficacy at non-toxic concentrations as well as to
overcome any drug resistance issues.
In summary, this study suggested that saracatinib shows antiviral activity at the early stages
of the MERS-CoV life cycle after internalization into Huh-7 cells through a possible mechanism of
suppressing SFK signaling pathways. In addition, we identified Fyn and Lyn kinases as additional host
factors involved in MERS-CoV infection. Thus, our results support the view that host kinases, such as
SFKs, play important role in coronavirus infection. Similarly, other FDA-approved kinase inhibitors
can be tested for antiviral activity against human coronaviruses and used as tools to identify novel host
kinases involved in virus replication. Moreover, the in vitro synergistic antiviral effect of saracatinib in
combination with gemcitabine against MERS-CoV infection suggests that lower therapeutic dosage
may be used to prevent any toxic side effect that the drug may have at therapeutic concentration.
Taken together, these findings provide insight into the potential use of clinically validated SFK kinase
inhibitors for the future development of new therapeutic options for highly pathogenic coronavirus
infection such as MERS-CoV.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/10/6/283/s1,
Table S1. Primer and probe sequences used in the RT-qPCR assay. Table S2. Antiviral activity of saracatinib against
other members of the Coronaviridae family. Figure S1. Assay validation of chemical library screening. Each dot
represents the Z’ score calculated from the cell control and virus control in each plate. Brifely, the Z’ score was
calculated using the formula: 1 − [(3σρ + 3ση)(|µρ − µη|)], where the µρ, σρ, and ση represent the means (µ)
and standard deviations (σ) of the positive (ρ) and negative (η) controls [20]. Figure S2. Saracatinib inhibits the
early stages of the MERS-CoV life cycle. Huh-7 cells were treated with 10 µM saracatinib for 1 h prior to virus
infection (pre) or 0.5% DMSO (virus control, VC), for 1 h during infection (co), at 1 h post-infection (post 1–24),
and at 4 h post-infection (post 4–24). After 24 h p.i., the total RNA isolated from the infected lysates were collected
and used for analyses of intracellular MERS-CoV genomic RNA (ORF1a, left panel) and mRNA (upE, right panel)
by RT-qPCR. Data represent means ± SD of two independent experiments performed in duplicate. Significant
differences are indicated by * p < 0.05, ** p < 0.01, *** p <0.001, **** p < 0.0001. Figure S3. Synergistic antiviral effect
of saracatinib and gemcitabine. MERS-CoV infected Huh-7 cells were simultaneously treated with a dose range of
1/2, 1, 2, and 4 of EC50 of saracatinib and gemcitabine and the combined antiviral effect was assessed using the
CellTiter 96® AQueous One Solution Cell Proliferation Assay. Data represent means ± SD of two independent
experiments performed in duplicate.
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